Read, Watch or Listen

Novo Nordisk reported a stronger-than-predicted first-quarter net profit of $4.4 billion, exceeding analyst expectations. However, the company lowered its full-year sales growth forecast due to competition from copycat weight-loss drugs. Wegovy sales, while up 83%, fell slightly short of projections. Overall revenue increased 18%, and Ozempic sales also surpassed forecasts. Despite the positive quarter, the revised sales growth forecast reflects the impact of generic competition.

Prepared by Christopher Adams and reviewed by editorial team.